RxDoctor Payments Data

Stephen Kuehn, MD

Interventional Cardiology · Washington, MONPI 1750317533

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.5%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Kestra Medical Technology Services, Inc. at 32.1% of the total. 2025 is the largest year on record at $21,568, 2.6 times the $8,266 reported in 2019.

$56,876in general payments, 2019–2025

Across 837 payments — averaging $67.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$18K
  • Johnson & Johnson$10K
  • Philips North America LLC$4K
  • Boston Scientific$3K
  • Medtronic$3K
  • Biotronik Inc.$3K
  • plus $16K from 41 others

What the payments were for

  • Consulting fees$4,8028%
  • Speaking & faculty fees$21,11137%
  • Travel & lodging$4,8659%
  • Food & beverage$25,85145%
  • Education$2470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$56,876 in reported general payments places this provider in the 85th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Medicare billing

Part B allowed, 2024
$63,681
Medicare patients
414
Services billed
771

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$51,741
XareltoRivaroxaban23$16,075
Repatha SureclickEvolocumab11$10,356
Praluent PenAlirocumab12$10,155
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$489
Atorvastatin Calcium72$423
Amlodipine Besylate59$360
Prasugrel Hcl14$356
Isosorbide Mononitrate ErIsosorbide Mononitrate41$303
Rosuvastatin Calcium22$303
ClopidogrelClopidogrel Bisulfate69$284
Metoprolol Succinate26$276
Ezetimibe21$252
Losartan Potassium33$249
Metoprolol Tartrate30$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,158$51,74168 claims
Johnson & JohnsonXarelto$10,306$16,07523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 interventional cardiology providers in Missouri.

Other interventional cardiology in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →